Logo FF-01.png
Fusion Fuel Green Hosts First Quarter 2022 Investor Update
May 26, 2022 06:35 ET | Fusion Fuel Green PLC
SABUGO, Portugal, May 26, 2022 (GLOBE NEWSWIRE) -- Fusion Fuel Green PLC (NASDAQ: HTOO) ("Fusion Fuel"), an emerging leader in the green hydrogen sector, today announced financial results for the...
ACM Logo.jpg
America's Car-Mart Reports Diluted Earnings per Share of $4.01 on Record Revenues of $352 Million
May 23, 2022 17:40 ET | America's Car-Mart, Inc.
ROGERS, Ark., May 23, 2022 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced its operating results for the fourth quarter and full fiscal year 2022. “Revenue grew 26% to...
Wilken, O’Shea Talk Acquisition of HS Pharmaceuticals and What It Means for The Future Of XCRT
May 23, 2022 08:00 ET | Xcelerate Inc.
AUSTIN, Texas, May 23, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Michael O’Shea, CEO of Xcelerate, Inc. (OTC Pink: XCRT, “Xcelerate”...
Cavco_Logo.png
Webcast Alert: Cavco Industries, Inc. Announces Fiscal 2022 Fourth Quarter and Year End Earnings Release and Conference Call Webcast
May 19, 2022 11:39 ET | Cavco Industries, Inc.
PHOENIX, May 19, 2022 (GLOBE NEWSWIRE) -- Cavco Industries, Inc. (Nasdaq: CVCO) will release earnings for the fourth quarter and fiscal year ended April 2, 2022 on Thursday, May 26, 2022 after the...
yield10.png
Yield10 Bioscience to Present at the H.C. Wainwright Global Hybrid Investment Conference
May 19, 2022 08:30 ET | Yield10 Bioscience, Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that President and CEO...
Arbutus Biopharma Logo
Arbutus to Present at H.C. Wainwright Global Investment Conference
May 17, 2022 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Obseva Logo highresolution.jpg
ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 17, 2022 01:00 ET | ObsEva SA
-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis:...
clarus_final_indentity.jpg
Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results
May 16, 2022 16:05 ET | Clarus Therapeutics Holdings, Inc.
First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year ...
CV_Sciences_logo2021.png
CV Sciences, Inc. Reports First Quarter 2022 Financial Results
May 16, 2022 09:00 ET | CV Sciences, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
Obseva Logo highresolution.jpg
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
May 16, 2022 07:00 ET | ObsEva SA
GENEVA, Switzerland May 16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company...